Search the Newsreel

Crexendo Inc (CXDO) Stock News Today

This article provides the latest news and financial data for Crexendo Inc (CXDO), a software and IT services company. It highlights the company's recent Q2 2026 earnings, where service revenue drove a 49% growth. The current stock price, market capitalization, and P/E ratio are …

Xenetic Biosciences: Q2 Earnings Snapshot

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Hold" recommendation from brokerages, with nine firms providing ratings. The biopharmaceutical company recently reported a quarterly loss of $0.29 per share, exceeding analyst estimates, and saw its revenue increase by 17.4% year over year. Several institutional investors …

Xenora Minerals (ASX:XRA) Shares Rise 11% as Dudley Lithium Work Continues

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

Xenon Pharmaceuticals' azetukalner NDA filing remains on track following a productive pre-NDA meeting with the FDA, according to RBC. However, the full article content is only available to premium subscribers.

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted significant progress in advancing azetukalner, with a successful pre-NDA meeting for focal seizures and a strong cash position of $1.2 billion, funding operations into 2029. The company also detailed its broad pipeline, including five additional …

Crexendo, Inc. (CXDO) CEO RSUs vest as 68 shares withheld for taxes

Crexendo, Inc. CEO Jeffrey G. Korn reported the vesting of 278 Restricted Stock Units (RSUs) into common stock on August 4, 2026. The company withheld 68 shares, valued at $7.47 each, to cover payroll tax obligations, a transaction explicitly stated not to be a …

Crexendo (CXDO) CFO notes 278 RSUs vested, 118 shares withheld for taxes

Crexendo, Inc.'s CFO, Vincent Ron, reported the vesting of 278 Restricted Stock Units (RSUs) on August 4, 2026. The company withheld 118 common shares at $7.47 per share to cover payroll taxes, clarifying that this was not a market sale. Ron retains 8,334 RSUs, …

Xenon Reports Q2 2026 Financial Results and Provides Business Update

Xenon Pharmaceuticals Inc. announced its Q2 2026 financial results, highlighted by the continued progress of its lead drug azetukalner, with an NDA submission for FOS on track for Q3 2026 and Phase 3 data for MDD expected in H1 2027. The company reported $1.2 …

Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary

Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily …

Earnings Flash (XENE) Xenon Pharmaceuticals Inc. Reports Q2 Revenue $0

Xenon Pharmaceuticals earnings on deck as FDA approval push nears

Xenon Pharmaceuticals is set to release its second-quarter earnings, with investors keenly watching its cash position and regulatory timeline as it approaches an FDA submission for its drug, azetukalner. Analysts anticipate a loss of $1.14 per share on $1.5 million in revenue. The company …

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting advancements in its oncology and autoimmune disease pipelines. Key updates include the progress of XmAb819 in clinical trials for various cancers, the advancement of XmAb942 and …

Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?

Xencor, Inc. reported mixed Q2 and half-year 2026 results, with a narrowing net loss for the quarter but a widened net loss for the first six months. This financial divergence highlights the impact of R&D spending on the company's profile and prompts a re-evaluation …

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

Xencor (NASDAQ:XNCR) shares reached a new 52-week high after reporting better-than-expected quarterly earnings and revenue. The biopharmaceutical company posted an EPS of $(0.29), significantly beating the consensus estimate of $(0.80), and revenue of $51.22 million, surpassing expectations. Despite remaining unprofitable with a negative net …

FMR LLC and Abigail Johnson report 9.9% Xenon Pharmaceuticals (XENE) holding

FMR LLC and Abigail Johnson have reported a 9.9% beneficial ownership stake in Xenon Pharmaceuticals Inc. (XENE) as of June 30, 2026. FMR LLC holds 9,599,498 common shares with sole dispositive power and sole voting power over 9,591,437 shares, while Abigail P. Johnson also …

Crexendo (CXDO) Stock Drops As Growth Strengthens But Earnings Lag

Crexendo (CXDO) stock recently dropped 11% despite strong Q2 2026 financial results, including a 48.9% revenue increase and a 17% adjusted EBITDA margin. While bulls point to significant growth in service and software solutions, bears highlight modest organic revenue growth and shifts in product …

Analysts Offer Insights on Communication Services Companies: Crexendo (CXDO), Pinterest (PINS) and Spotify (SPOT)

This article provides an overview of recent analyst ratings for three communication services companies: Crexendo (CXDO), Pinterest (PINS), and Spotify (SPOT). Crexendo received a "Strong Buy" consensus with a $11.00 average price target, Pinterest a "Moderate Buy" with a $29.00 average price target, and …

Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary

Xencor Inc reported its second-quarter 2026 results, showing a revenue increase to $51.22 million from $43.61 million year-over-year. Despite the revenue growth, the company posted a net loss of ($21.73 million) and a diluted loss per share of ($0.29). Key drivers included higher royalties …

Responsive Playbooks and the CXDO Inflection

This article provides an AI-generated analysis of Crexendo Inc. (NASDAQ: CXDO), highlighting positive near-term sentiment within a long-term strong context, despite a weak mid-term bias. It outlines exceptional risk-reward setups, specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop-loss zones, and a multi-timeframe …

Xencor (XNCR) Stock Drifts As Revenue Lands But Profit Path Stays Murky

Xencor Reports Second Quarter 2026 Financial Results

Xencor, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its clinical pipeline and strategic partnerships. Key updates include planned presentations for XmAb819 at ESMO 2026, continued enrollment for XmAb942 in the XENITH-UC study, and the initiation of a first-in-human study for …

Xencor Inc earnings beat by $0.51, revenue topped estimates

Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M

Xencor (NASDAQ: XNCR) reported a Q2 2026 net loss of $21.7 million, narrowing from $30.8 million in Q2 2025, on revenues of $51.2 million. The company also announced a post-quarter-end settlement with Alexion for $105 million, resolving a U.S. royalty dispute related to Ultomiris …

Xenia Hotels & Resorts launches $200M at-the-market equity program with major banks

Xenia Hotels & Resorts (XHR) has initiated an "at-the-market" equity distribution program to offer up to $200 million of common stock through designated managers including Jefferies, BofA, and Goldman Sachs. The proceeds from any sales will be used for general corporate purposes, such as …

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

Xencor (NASDAQ:XNCR) reported quarterly EPS of ($0.29), significantly beating analyst expectations of ($0.80) by $0.51, despite maintaining a negative net margin. The biopharmaceutical company's shares traded near $19.84, close to its 52-week high, with major institutional investors like Goldman Sachs and JPMorgan increasing their …

Crexendo, Inc. (CXDO) CTO discloses stock options, RSUs and shares

Crexendo, Inc.'s Chief Technology Officer, Christopher Ryan Aaker, has filed an initial statement of beneficial ownership (Form 3) detailing his equity holdings. His holdings include stock options for 30,000 common shares with varying exercise prices and expiration dates, restricted stock units (RSUs) totaling 42,501 …

Crexendo (NASDAQ:CXDO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Crexendo (NASDAQ:CXDO) announced its quarterly earnings, reporting $0.12 EPS, beating analyst expectations by $0.02, with revenue matching estimates at $24.65 million. Despite positive operational growth, including a 49% increase in second-quarter revenue and significant gains in operating cash flow, the stock experienced a 9.7% …

Nexxen International (NEXN) Projected to Release Quarterly Earnings on Wednesday

Nexxen International (NEXN) is scheduled to release its Q2 2026 earnings on Wednesday, August 12th, with analysts anticipating earnings of $0.17 per share and revenue of $92.8 million. The stock is currently trading near its 12-month high, demonstrating positive momentum above its moving averages, …

Xencor: Q2 Earnings Snapshot

Xencor Inc. reported a Q2 loss of $21.7 million, or 29 cents per share, which surpassed Wall Street's expectation of an 82-cent loss per share. The biotech company also posted revenue of $51.2 million, significantly beating the Street forecast of $11.7 million. These results …

B. Riley Adjusts Price Target on Crexendo to $9 From $10, Maintains Buy Rating

B. Riley has revised its price target for Crexendo (CXDO) shares down to $9 from $10, while still maintaining a Buy rating on the stock. This adjustment comes despite the firm's continued positive outlook for the company. The article also mentions recent news about …

Crexendo Q2 2026 earnings: Service revenue drives 49% growth

Crexendo (CXDO) reported a 49% year-over-year revenue increase to $24.6 million in Q2 2026, primarily driven by service revenue. Despite this growth, GAAP diluted EPS declined to $0.03 from $0.04 due to operating expenses growing slightly faster than revenue. The company saw higher non-GAAP …

CXDO|Crexendo Inc|Price:7.450|Chg%:+0.230

Crexendo Inc (CXDO) is a software technology company focused on cloud communication and IT services. The company's stock currently trades at $7.450, up 3.19%, with a market capitalization of $241.33 million. Analysts rate CXDO as a "Buy" with a target price of $11.17, suggesting …

Xencor (XNCR) Earnings Date and Reports 2026

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates